Informed Consent Process and Procedures for Clinical Research
Objectives

- List and describe supporting documentation of the informed consent process (e.g. consent forms, consent notes, waivers).
- Identify and interpret policies and regulations related to the informed consent process and HIPAA
- Describe requirements related to ensuring participant comprehension of informed consent and ICFs (e.g. translation requirements)
- Describe how the consent process is planned and diagnose errors in consent planning
- Describe the procedure for conducting and documenting consent for participants
Refresher: What is Informed Consent?

“A process by which a subject voluntarily confirms his or her willingness to participate in a particular trial, after having been informed of all aspects of the trial that are relevant to the subject’s decision to participate. Informed consent is documented by means of a written, signed and dated informed consent form.”

FDA’s Guidance for Industry E6 GCP: Consolidated Guidance, Section 1.28
My Informed Consent form was approved by the IRB! Now what?

• The IRB approval letter, relevant communications, and approved ICF should be filed in the site’s regulatory binder and saved electronically

• If applicable, send sponsor a copy of the IRB approval letter and approved ICF
Changing the Informed Consent Form

- Any revised written ICF document and written information must be submitted for IRB approval prior to use.
  - Revise the ICF whenever important new information becomes available that may be relevant to the subject’s consent or willingness to continue participation in the trial.
  - If the IRB of record is not LSUHSC, all new and revised documents relevant to LSUHSC should still be submitted to the LSUHSC IRB, preferably within 30 days.
    - For example, if WIRB is the central IRB, the updated consent for LSU patients would still need to be submitted to LSUHSC IRB.
- Change the document version number and approval date on the updated ICF.
- Submit tracked Word document and clean PDF of the updated ICF.
Before you get started...

Are you listed as Study Personnel in the IRB submission and Delegation of Authority Log?

What does the protocol say?
E.g., location of consent, in-person vs. phone

Do you have the UP TO DATE version of the consent?

Consenting is an ongoing process. Some studies have multiple updates.

Check before you consent.
Informed Consent Process

Investigator or sub-investigator presents the consent form with the potential participant, and allows ample time for the potential participant to ask questions.

The potential participant may be provided with a copy of the consent and given time to consider whether they want to participate.

After allowing the participant time to decide, the Investigator or designee (e.g., coordinator) must answer any additional questions the subject may have.

When the potential participant is ready, the Investigator or designee must obtain signatures on the consent & HIPAA Authorization or document verbal consent (unless waiver applies).
Signing the Consent & HIPAA Authorization

Who Can Sign? Participant or their Legally Authorized Representative*

What if the Participant Cannot Write? The participant can sign with an “X”

What if the Participant Cannot Read? An independent witness must be present for the reading of the consent & HIPAA Authorization. There is a signature block on the consent form for the witness.

*Remember: LAR cannot sign in the case of nonviable neonates.
Short Forms for Non-English Speakers

• Used when consenting a subject unexpectedly that does not speak English.
• The full consent form must be translated verbally to the subject by a translator or a study team member who is proficient in the participant’s primary language.
• **Witness must be present and conversant in both languages** (i.e., English and the language of the subject).
  • If study team member does verbal translation, an independent witness must also be present.
• A copy of the short form is given to the subject/LAR.
• Only sign the forms written in languages that the person understands!
  • Subject/LAR only sign short form itself.
  • Witness should sign both the short form and copy of the summary
  • The person actually obtaining consent shall sign a copy of the summary.
• If the study team anticipates enrollment of non-English speaking participants, it is their responsibility to get the full consent form certified, translated.
  • Once the short form has been used twice, the study team needs to get the full consent form translated.
• LCMC and UMC use a translation phone service. Make sure you document the ID number of the translator used.
LSUHSC has short forms and HIPAA Authorizations pre-translated into Spanish, French, and Vietnamese.
Emergency Preparedness

• Active participants who are either **taking study drugs or devices** should receive a copy of the **emergency contact number** and the IRB-approved **emergency card** with their study ID number.

• Make sure all the information (principal investigator name, phone number and email address) is accurate prior to giving it to participants.
A description of the clinical trial will need to be available at http://www.ClinicalTrials.gov, as required by U.S. Law.

ClinicalTrials.gov is a website that provides information about federally and privately supported clinical trials.

During the consent process, study team members need to explain what ClinicalTrials.gov is to participants, how to access information about their trial, and emphasize that the website will not include information that can identify them.
After the Participant Signs

- **Review the signed form for completeness** BEFORE subject leaves and again BEFORE filing in your files.
  - Ensure that all blanks on the forms are filled out appropriately
  - Research team members may not complete these blanks for the subject
- **The complete original signed copies** are kept by PI and delegated study team members
  - Put the original copy in the regulatory binder and a copy of the signed ICF in the subject file
- **Provide a copy of all signed forms to the subject/LAR**
- Document informed consent process in source document
- **Remember! Consent is an ongoing process!**
- Same procedure and process applies for **re-consenting** subjects
  - Re-consent when participant turns 18 years old
Template to Document IC Process in EPIC for UMC/LCMC

Research Informed Consent Documentation Form

@LCMCTODAYDATE@

Protocol Name: ***
Protocol #: ***
IRB #: ***
Principal Investigator: ***
Version: ***
IRB Approval Date: ***

Subject has the ability to give informed consent? (yes/no:310449)
Legal Representative gave informed consent on behalf of the subject and has the authority to act on behalf of the subject? (yes/no:310449)
The Informed Consent was obtained prior to any study procedures being performed? (yes/no:310449)
Was the informed consent discussion in private & did the subject have enough time to read the consent? (yes/no:310449)
Has the subject had enough time to ask questions of qualified staff? (yes/no:310449)
Has the subject expressed comprehension of the Goal of the Research and Protocol? (yes/no:310449)
Has the subject expressed comprehension of the Duration of Participation? (yes/no:310449)
Has the subject expressed comprehension of the Risks with Study Medication and Procedures? (yes/no:310449)
Has the subject expressed comprehension of the Benefits and Compensation? (yes/no:310449)
Has the subject expressed comprehension of Voluntariness? (yes/no:310449)
Has the subject expressed comprehension of the reproductive risks related to study medication or procedures? (yes/no:310449)
Has the subject expressed comprehension of the process for New Information? (yes/no:310449)
Has the subject expressed comprehension of the Privacy & Confidentiality? (yes/no:310449)
Has the subject expressed comprehension regarding compensation for study related injury and whom to contact for study related injury? (yes/no:310449)
Does the subject have all the proper Contact Information required? (yes/no:310449)
Was the subject given a Copy of the completed Consent Form? (yes/no:310449)
Has the subject expressed comprehension regarding compensation for study related injury and whom to contact for study related injury? (yes/no:310449)
Does the subject have all the proper Contact Information required? (yes/no:310449)
Was the subject given a Copy of the completed Consent Form? (yes/no:310449)

Patient stated @HIS@ willingness to participate in the study. All questions and/or concerns were answered to the patient and @HIS@ legal representative/guardian’s satisfaction by myself and the treating physician. ***
Waivers

- Waiver of Informed Consent
- Waiver of Documentation of Informed Consent / Permission for Verbal Consent
- Waiver or Alteration of HIPAA Authorization
Waiver of Informed Consent

The IRB may approve a waiver of the requirement to obtain informed consent if **all** of the following apply:

1. **Is research more than minimal risk?**
   - No
   - Yes
   - *Waiver cannot be approved*

2. **Will waiver adversely affect the rights/welfare of subjects?**
   - No
   - Yes
   - *Waiver cannot be approved*

3. **Can the research be practically carried out without the waiver?**
   - No
   - Yes
   - *Waiver cannot be approved*

4. **Will subjects be provided with additional pertinent information after participation?**
   - No
   - Yes
   - *Waiver of Informed Consent Approved*
The IRB may approve a waiver of documentation of informed consent and/or grant permission to obtain verbal consent if any of the following apply:

45 CFR 67.117(c)(i)
- The only record linking the subject and the research would be the signed informed consent form;
- The principal risk would be potential harm resulting from a breach in confidentiality; and,
- Each subject or LAR will be asked whether the subject wants documentation linking them.

45 CFR 67.117(c)(ii)
- The research presents no more than minimal risk of harm to subjects; and,
- The research involves no procedures for which written consent is normally required outside of the research context

45 CFR 67.117(c)(iii)
- The subject or LAR is a member of a distinct cultural group or community in which signing forms is not the norm;
- The research presents no more than minimal risk of harm to subjects; and,
- There is an appropriate, alternative mechanism for documenting that informed consent was obtained.
Verbal Informed Consent
Information Sheet and Script

- When the documentation requirement is waived and verbal informed consent is allowed, the study team must provide the subject with an information sheet (either printed or electronically).
- When verbal consent is obtained over the phone for informed consent, the study team is also required to have a script to be used by the person obtaining consent.
- When the waiver is granted under 45 CFR 67.117(c)(i) (only record linking subject and research is signed ICF), person consenting must provide option for subject/LAR to sign the verbal ICF document (e.g., script and/or information sheet).
- When waiver is granted under other categories, person consenting must sign the information sheet if consenting in person or the verbal script if consenting via phone or via other electronic means.
- Person consenting should also document how verbal consent was obtained.
Waiver or Alteration of HIPAA Authorization

The IRB may approve a waiver of or alteration to HIPAA Authorization if any of the following apply:

45 CFR 164.512(i)(ii)(A)

• The use or disclosure of protected health information involves no more than minimal risk to the privacy of the subjects based on, at least, one of the following:
  i. An adequate plan to protect the identifiers from improper use or disclosure; and/or,
  ii. An adequate plan to destroy the identifiers at the earliest opportunity, unless there is a health, legal, or research justification for retaining the identifiers; and/or,
  iii. Adequate written assurances that the protected health information will not be used or disclosed to any other person or entity, except as required by law for authorized oversight of the research project, or for other research for which the use or disclosure of protected health information would be permitted.

45 CFR 164.512(i)(ii)(B)

• The research could not practicably be conducted without the waiver or alteration

45 CFR 164.512(i)(ii)(C)

• The research could not practicably be conducted without access to and use of the protected health information
Verbal HIPAA Information Sheet and Script

- In cases where HIPAA authorization requirement is altered and verbal HIPAA authorization is allowed, the study team may be required to provide the subject with a **HIPAA Authorization document without subject information lines and signature lines** (either printed or electronically).
- When HIPAA authorization is obtained over the phone for informed consent/HIPAA, the study team is also required to have a **script to be used by the person obtaining consent/authorization**.
- When the **waiver is granted under 45 CFR 67.117(c)(i)** (**only record linking subject and research is signed ICF**), person consenting must **provide option for subject/LAR to sign the verbal HIPAA document** (**e.g., script and/or information sheet**).
- When waiver is granted under **other categories**, person consenting must **sign the information sheet if consenting in person** or the **verbal script if consenting via phone or via other electronic means**.
- Person consenting should also **document how verbal HIPAA was obtained**.
Waiver of Parental Permission
(45 CFR §46.408(c)/45 CFR §46.116(c))

• The research or demonstration project is to be conducted by or subject to the approval of state or local government officials and is designed to study, evaluate, or otherwise examine
  i. public benefit or service programs;
  ii. procedures for obtaining benefits or services under those programs;
  iii. possible changes in or alternatives to those programs or procedures; or
  iv. possible changes in methods or levels of payment for benefits or services under those programs.
• The research could not practically be carried out without the waiver or alteration.
Waiver of Parental Permission
(45 CFR §46.408(c)/45 CFR §46.116(d))

• The research involves no more than Minimal Risk to the subjects.
• The waiver or alteration will not adversely affect the rights and welfare of the subjects.
• The research could not practicably be carried out without the waiver or alteration.
• Whenever appropriate, the subjects will be provided with additional pertinent information after participation.
• The research protocol is designed for conditions or for a subject population for which parental or guardian permission is not a reasonable requirement to protect the subjects.
• An appropriate mechanism for protecting the children who will participate as subjects in the research is substituted.
• The waiver is not inconsistent with Federal, State, or local law.
Waiver of Assent
(45 CFR §46.408(a)/45 CFR §46.116(c))

• The research is **not FDA-regulated**.
• The research or demonstration project is to be conducted by or subject to the approval of **state or local government officials**
• The research or demonstration project is designed to study, evaluate, or otherwise examine one or more of the following:
  i. (i) Public benefit or service programs.
  ii. (ii) Procedures for obtaining benefits or services under those programs.
  iii. (iii) Possible changes in or alternatives to those programs or procedures.
  iv. (iv) Possible changes in methods or levels of payment for benefits or services under those programs.
• The research **could not practicably be carried out** without the waiver or alteration.
Waiver of Assent
(45 CFR §46.408(a)/45 CFR §46.116(d)/21 CFR §50.55(d))

- The research involves no more than Minimal Risk to the subjects.
- The waiver or alteration will not adversely affect the rights and welfare of the subjects.
- The research could not practicably be carried out without the waiver or alteration.
- Whenever appropriate, the subjects will be provided with additional pertinent information after participation.
The study team knows that they need to retain the original signed copy of the consent form. They have kept the last page of the consent document in the study files, since this is the only page with signatures.

What is the issue?
The study team knows that they need to retain the original signed copy of the consent form. They have kept the last page of the consent document in the study files, since this is the only page with signatures.

What is the issue?

The study team must retain the full original copy of the signed form, not just the page with signatures.
As their IC procedures, the study team member wants to provide the participant with a copy of the consent document and ask them to read it over and ask questions.

What is the issue?
As their IC procedures, the study team member wants to provide the participant with a copy of the consent document and ask them to read it over and ask questions.

What is the issue?

The study team member needs to have a **dialogue** with the participant and go through the entire consent with the subject. The consent acts as a guide for the conversation.
True or false?
The regulations strongly suggest but do not require that the informed consent process be delivered in a language that is understandable to the subject.
True or false?

The regulations strongly suggest but do not require that the informed consent process be delivered in a language that is understandable to the subject.

FALSE.

The information that is given to the subject or the representative must be in language understandable to the subject or the representative.
Can you provide an example of when a waiver of consent/assent may be appropriate?
Can you provide an example of when a waiver of consent, assent, or parental permission may be appropriate?

Example 1: A medical record chart review study
Example 2: A study with participants under the age of 18 about sexual activity, STDs, use of illegal substances, HIV status, cancel, and child abuse
Implementing Effective Informed Consent

Knowledge
• Relevant information disclosed

Appreciation
• How the information applies to the subjects’ own interests and preferences
<table>
<thead>
<tr>
<th>Participant Factors</th>
<th>Study Team Factors</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Low Health Literacy</td>
<td>• Lack of time</td>
</tr>
<tr>
<td>• Limited English Proficiency</td>
<td>• Overly complex materials</td>
</tr>
<tr>
<td>• Cognitive Impairment</td>
<td>• Lack of interpreter support</td>
</tr>
<tr>
<td>• Learning Disabilities or Educational Level</td>
<td>• Wrong assumptions about patient comprehension</td>
</tr>
<tr>
<td>• Hearing/Vision Impairment</td>
<td></td>
</tr>
<tr>
<td>• Confusion about the process &amp; its purpose</td>
<td></td>
</tr>
<tr>
<td>• Intimidation</td>
<td></td>
</tr>
<tr>
<td>• Stress or Time Pressure</td>
<td></td>
</tr>
<tr>
<td>• Memory</td>
<td></td>
</tr>
<tr>
<td>• Therapeutic Misconception</td>
<td></td>
</tr>
</tbody>
</table>
Therapeutic Misconception

Sigh...

So what I hear you saying is you'll pay me to get cured—I'm in!!
Other Barriers: Coercion

Occurs when an overt or implicit threat of harm is intentionally presented by one person to another in order to obtain compliance.

Example: Investigator tells prospective participants that they will lose access to needed health services if they do not participate in the research.
Other Barriers: Undue Influence

Often occurs through an offer of an excessive or inappropriate reward or other overture in order to obtain compliance.

Example: Investigator promises psychology students extra credit if they participate in the research. If that is the only way a student can earn extra credit, then the investigator is unduly influencing potential participants. If, however, she offers comparable non-research alternatives for earning extra credit, the possibility of undue influence is minimized.

Undue Influence can be subtle.

Example: Patients might feel obligated to participate in research if their physician is also the investigator, or students might feel pressure to participate in research if everyone else in the class is doing so.
Minimizing Coercion and Undue Influence

• Reasonable assessments can be made by the IRB to minimize the likelihood of undue influence or coercion occurring.
  Example: restricting levels of financial or nonfinancial incentives for participation, carefully reviewing how incentives are described to potential participants.

• It is up to the IRB to use its discretion in determining which circumstances give rise to undue influence.
  Example: an IRB might consider whether the informed consent process will take place at an appropriate time and in an appropriate setting, and whether the prospective participant may feel pressured into acting quickly or be discouraged from seeking advice from others.

• Known benefits should be stated accurately but not exaggerated, and potential or uncertain benefits should be stated as such.
Tips for Improving Patient Communication

• Practice!
• Be empathetic and honest
• Keep it simple and do not rush
• Speak slowly and use easy-to-understand speech
• Observe the participant’s body language
• Get a sense of what the participant already knows and what the participant wants to know
• Recognize differences in education or literacy
• Consent document guides your interactions and supports the consent process
• Consider using supplementary materials (must be IRB-approved)
Tips for Improving Patient Communication

- Actively **assess for understanding**
  - Teach-Back
  - Open-ended
- Make sure participants are given **opportunity to decline** and are **aware of their right to do so**
  - Are **confidential procedures** for consent or refusal needed?
- Allow potential participants to **take the forms home** to review
  - Make sure participants do not sign until study team member is present!
- **Principal Investigator or delegate** should be available to answer questions
- Develop a **system to track** consents and re-consents
- After participation is complete, **get feedback** about the consent process
Check for Understanding:

Can you give an example of coercion?
Can you give an example of coercion?

Examples:

Imagine a professor doing survey research about sensitive and private topics who wishes to use their students as participants, and who threatens to fail or penalize any students who do not complete the survey.

Imagine a physician who threatens to withhold access to some service or product unless their patient participates in a research study that they are conducting.

Imagine an investigator threatens to pay a participant less than was promised at initial consent unless they continue in the trial.

The Many Faces of “Coercion” and “Undue Influence”
LSU Health Coordinator Competencies

- Onboarding
- Ethical Standards
- Protocol Compliance
- Developing the Informed Consent Form
- Informed Consent Process and Procedures
- Patient Recruitment & Retention
- Management of Patients
- Documentation & Document Management
- Data Management & Information Technology
- Financial Stewardship
- Leadership & Professional Development
Links to Regulations

**Belmont Report**
**Common Rule** (45 CFR 46)
FDA Regulations (21 CFR 50 & 56)
**ICH Good Clinical Practice**
References


